Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
American Society for Clinical Oncology (ASCO) GI
Jan 23
- Jan 25, 2025
Preliminary Results From a Randomized, Open-Label, Phase 2 Study of Botensilimab With or Without Balstilimab in Refractory Microsatellite Stable Metastatic Colorectal Cancer With No Liver Metastases
Fakih, et al.
Filter by
AGEN1327 (TIGIT Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity.
Ward, et al.
AGEN1327 (TIGIT Antagonist)
American Association for Cancer Research (AACR)
Mar 29
- Apr 3, 2019
FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses.
Chand, et al.